Year: 2024
Type: article
Study design: Case Report
Abstract: Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allowed for treatment of the AML. After one year, with stable renal function and genetic studies reported as normal, eculizumab was successfully discontinued. The prompt use of eculizumab was critical to the patient's survival and improvement in renal function, highlighting the efficacy of early eculizumab treatment in secondary HUS.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm13216468
Authors: Jonas El Bachouti, Anna Domínguez-Guasch, Yolanda Arce, Guadalupe Oñate, Helena Marco, Montserrat Diaz, Lluís Guirado, Roser Torra, Xoana Barros
Institutions: Puigvert Foundation, Hospital de Sant Pau
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,955
OpenAlex ID: W4403829017